Promucetin, a new C-type lectin-like protein modulate coagulation by activating platelets through GPIB

Abstract

History: Snake Venom C-Type Lectin proteins (also known as Snacecs) have anticoagulation effects and procuculation IX / x, has suggested their potential as candidates for new anticoagulant drugs. Therefore, this study intends to evaluate antiplatelet and antithrombrotic effects of a new SNACLEC from Protobothroprops Mucrosquamatus venom and potential as an anticoagulant candidate. Ways: Promucetin is cleaned by successive column chromatography, and molecular mass is determined on the SDS page. Α- and β-chain of promucetin are recognized using liquid chromatography-mass spectrometry (LC-MS). In Vitro The analysis of the platelet mixture is held using turbidimetric methods, thromboelasography, and caagulation assays activity. consideration in vain Experiments, Promucetin were administered by rats in various concentration, and platelet changes were monitored. Antithrombromotic Promcetin Effects are checked using a Pecl₃-Model Model Model Model. Results: Promucetin exists as two multimers with molecular weights of 140.1 KDA and 91.9 KDA under reduced conditions. Sequence analysis reveals that α-chain and β-chain divided by 71% and 34% homology, with TMVA from the same snake snake. In Vitro Platelet asserts indicate attices that promucetin activates platelets through glycoprotein IB. Thromboelastromography shows that Promucetin prevents the activity of a coagulation cause and platelet function, resulting in an anticoagulant effect. Specifically, the time of thrombin long, while activated partial thrombollastin time and the prothrombin time remained unchanged. In vainThe Promucceucin administration brings a dose that depends on the platelet’s reduction. Of doses of 25 and 50 μg / kg, promucetin significantly preventing thrombosis, with restriction restrictions at 40.9% and 74.4%. For comparison, lysine acetylsalicylicylate makes a ribation rate at 36.7%. Conclusion: Promucetin shows the essential ability to change the coagulation function and effective thrombosis with activation of the GPICICT platelet to be a candidate for a candidate for anticoagulant therapy.